文献速递泌尿生殖骨肌技术与安全CT

采用xSPECT Quant定量SPECT/CT定量去势抵抗性前列腺癌正常骨与骨转移灶:帕博利珠单抗联合镭-223对比单用镭-223的2期临床试验的前瞻性影像学子研究

Quantification of normal bone and osseous metastases in castration-resistant prostate cancer using SPECT/CT with xSPECT Quant: prospective imaging sub-study of a phase 2 clinical trial investigating the combination of pembrolizumab plus radium-223 compared to radium-223 alone.
PubMed 文献 · Radiol Med · 2024-11-20

本前瞻性影像学子研究纳入21例转移性去势抵抗性前列腺癌患者(15例有配对基线与首次再分期数据),采用1.5 cm ROI在CT及xSPECT Quant重建上测量正常骨与转移灶的SUVmax和HUmean。基线转移灶中位SUVmax为42.2 g/mL,约为正常骨5.85 g/mL的7.2倍;首次再分期靶病灶SUVmax中位下降40.1%(p<0.001),HUmean中位升高8.3%(p=0.0479)。

要点

  • 正常骨中位SUVmax 5.85 g/mL、HUmean 133.03,可作为定量参考。
  • 基线转移灶中位SUVmax 42.2 g/mL,约为正常骨的7.2倍。
  • 首次再分期靶病灶SUVmax中位下降40.1%、HUmean中位升高8.3%。

核心结论

  • 定量SPECT/CT可提供一致、客观的影像参数,有助于监测肿瘤负荷;基线转移灶中位SUVmax约为正常骨的7.2倍;定量SPECT/CT可能有助于显示单用镭-223或联合帕博利珠单抗治疗前列腺癌患者的早期成骨性治疗反应。

研究设计与样本

  • 前瞻性影像学子研究,作为一项2期临床试验(NCT03093428)的一部分。

关键影像表现/征象

  • 正常骨中位SUVmax为5.85 g/mL(范围0.42-14.98),中位HUmean为133.03(范围28.47-461.91)。
  • 转移灶中位SUVmax为42.2 g/mL(范围17.96-143.36),中位HUmean为549.58(范围177.87-1107.64)。
  • 靶病灶SUVmax中位变化-40.1%(范围-86.2%至+23.5%),HUmean中位变化+8.3%(范围-11.3%至+61.7%)。

诊断标准与关键数值

  • 在CT及xSPECT Quant重建图像上,采用1.5 cm感兴趣区(ROI)测量SUVmax和HUmean。
  • 选取基线(S0)每个患者示踪剂摄取最高的转移灶作为靶病灶,在首次再分期扫描(S1)上比较其SUVmax和HUmean变化。
  • 靶病灶SUVmax下降-40.1%(p<0.001),HUmean升高+8.3%(p=0.0479,Wilcoxon符号秩检验)。
  • 靶病灶SUVmax百分比变化与血清PSA(r=0.33,p=0.226)及ALP(r=0.45,p=0.094)的Spearman相关性均未达统计学显著。

临床应用与阅片要点

  • 定量SPECT/CT可提供一致、客观的影像参数,有助于监测肿瘤负荷。
  • 定量SPECT/CT可能有助于显示单用镭-223或联合帕博利珠单抗治疗前列腺癌患者的早期成骨性治疗反应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: The purpose of this study is to demonstrate the consistency and reproducibility of quantitative SPECT/CT by evaluating the maximum SUV (SUVmax) in normal bone, to provide the reference value of metastatic lesions, and to evaluate the clinical implication of SUVmax changes of osseous metastasis during treatment.

MATERIAL AND METHODS: This prospective imaging sub-study was performed as part of a phase 2 clinical trial of patients with metastatic castration-resistant prostate cancer (mCRPC) randomized to the combination of pembrolizumab plus radium-223 or to radium-223 alone (NCT03093428). The maximum standardized uptake value (SUVmax) and mean Hounsfield Unit (HUmean) of normal bone as well as metastases were measured using a 1.5 cm region of interest (ROI) on CT and xSPECT Quant reconstruction on the baseline study (S0) and restaging scans. The most tracer-avid metastatic lesion in each patient on S0 was selected as a target lesion, and changes of SUVmax and HUmean of the target lesion were compared on the first restaging scan (S1). Correlations between the percentage changes of SUVmax of the target lesion with alkaline phosphatase (ALP) and prostate-specific antigen (PSA) were assessed.

RESULTS: Twenty-one patients were enrolled on the imaging sub-study of which 15 had paired baseline S0 and S1 data. On S0, the median SUVmax and HUmean of normal bone was 5.85 g/mL (0.42-14.98) and 133.03 (range, 28.47-461.91), respectively. The median SUVmax and HUmean of metastasis were 42.2 g/mL (range, 17.96-143.36) and 549.58 (177.87-1107.64), respectively. There was significant reduction in SUVmax (- 40.1%, range - 86.2 to + 23.5%), p < 0.001) and increase in HUmean (+ 8.3%, range - 11.3 to + 61.7%, p = 0.0479, Wilcoxon signed-rank test) of target lesions between S0 and S1. Spearman correlation between the percentage changes of SUVmax of a target lesion and both serum PSA (r = 0.33, p = 0.226) and ALP (r = 0.45, p = 0.094) were not statistically significant.

CONCLUSION: Quantitative SPECT/CT provides consistent and objective imaging parameters, which can help monitor tumor burden. The median SUVmax of metastasis at baseline was roughly 7.2-fold higher than normal bone. Quantitative SPECT/CT may help visualize the early osteoblastic treatment response in prostate cancer patients treated with radium-223 alone or combined with pembrolizumab.

来源:Radiol Med,查看原文。版权归原作者所有。

引用

  1. Robertson MS, Wang Y, Cheng S, et al. Quantification of normal bone and osseous metastases in castration-resistant prostate cancer using SPECT/CT with xSPECT Quant: prospective imaging sub-study of a phase 2 clinical trial investigating the combination of pembrolizumab plus radium-223 compared to radium-223 alone. Radiol Med. 2024. PMID: 39565570. doi:10.1007/s11547-024-01931-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。